Life Sciences Lunch Series: The Cost of Delayed Cancer Diagnoses
As a result of the pandemic, 2020 saw a large drop-off in the screening rates for many types of cancer. In general, cancer is easier to treat when identified in early stages and “missed” cancers may be larger or more advanced when ultimately detected. While the impact of the pandemic on overall cancer deaths will not be clear for many years, it has produced both reasons for concern and optimism.
Please join us as our panel discusses the impact of COVID-19 on cancer screenings, whether the trend is reversing, and how innovation – particularly around multi-cancer early detection – may help current and future patients.
Questions? Email Lindsay Hulliberger or call 312-214-5661.